Fore (Drug Discovery) Overview
- Founded
-
2011
- Status
-
Private
- Employees
-
38
- Latest Deal Type
-
Series C
- Investors
-
15
Fore (Drug Discovery) General Information
Description
Operator of a clinical-stage biotechnology company intended to develop selective medicines for functionally and genomically defined cancer patients. The company's clinical-stage drug development aids to recapitulate naturally occurring mutations in vitro and tests their effect on signaling pathway activity and their response to different compounds, enabling biopharma companies to get support in identifying new target mutations and expanded subgroups of cancer patients to respond to existing therapies.
Contact Information
Website
www.fore.bio
Formerly Known As
NovellusDx
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- 3675 Market Street
- Philadelphia, PA 19104
- United States
+1 (215) 000-0000
Fore (Drug Discovery) Timeline
Fore (Drug Discovery) Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Later Stage VC (Series C) | 01-Feb-2022 | 000.00 | Completed | Clinical Trials - Phase 1 | ||
| 7. Later Stage VC (Series C) | 21-Sep-2020 | 0000 | 000.00 | Completed | Clinical Trials - Phase 1 | |
| 6. Merger/Acquisition | 17-Dec-2018 | Cancelled | Clinical Trials - Phase 1 | |||
| 5. Later Stage VC | 30-Apr-2018 | 000 | 000.00 | 00.00 | Completed | Clinical Trials - Phase 1 |
| 4. Grant | 31-Jan-2017 | 00000 | 000.00 | Completed | Clinical Trials - Phase 1 | |
| 3. Later Stage VC (Series A) | 22-Jun-2016 | 000.00 | 000.00 | 000.00 | Completed | Clinical Trials - Phase 1 |
| 2. Seed Round | 01-Jan-2014 | $1.14M | $5.14M | Completed | Clinical Trials - Phase 1 | |
| 1. Seed Round | 01-Jul-2013 | $4M | $4M | Completed | Clinical Trials - Phase 1 |
Fore (Drug Discovery) Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Operator of a clinical-stage biotechnology company intended to develop selective medicines for functionally and genomica
Drug Discovery
Philadelphia, PA
38
As of 2022
000.00
00000000000
000.00
000000
minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Dui
0000 000000000
Roseville, MN
00
As of 0000
000.00
000000&0
000.00
00 000
dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore ma
0000 000000000
Copenhagen, Denmark
00
As of 0000
00000
0000
0000-00-00
00000000
00000
Add Comparison
Fore (Drug Discovery) Competitors (52)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Biothera Pharmaceuticals | Formerly VC-backed | Roseville, MN | 00 | 000.00 | 000000&0 | 000.00 |
| 00 0000000 | Formerly VC-backed | Copenhagen, Denmark | 00 | 00000 | 00000000 | 00000 |
| 000000000 | Formerly VC-backed | Gaithersburg, MD | 00 | 00000 | 00000000 | 00000 |
| 000000000 00000000 | Venture Capital-Backed | Mountain View, CA | 00 | 000.00 | 000000000 - | 000.00 |
| 000000 00000000000 | Corporation | Cambridge, MA | 000 | 00000 | 000000 - 000 | 00000 |
Fore (Drug Discovery) Patents
Fore (Drug Discovery) Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-2970897-A1 | Systems, devices, kits and methods for seeding cells or sets of molecules in an array on a substrate | Abandoned | 15-Dec-2014 | 000000000 | |
| US-20170362557-A1 | Systems, devices, kits and methods for seeding cells or sets of molecules in an array on a substrate | Abandoned | 15-Dec-2014 | 000000000 | |
| EP-3234103-A4 | Systems, devices, kits and methods for indirect transfection of multiple sets of nucleic-acids and transfer of molecules | Withdrawn | 15-Dec-2014 | 00000000000 | 0 |
| US-20170362588-A1 | Systems, devices, kits and methods for indirect transfection of multiple sets of nucleic-acids and transfer of molecules | Abandoned | 15-Dec-2014 | 00000000000 | |
| CA-2970900-A1 | Systems, devices, kits and methods for indirect transfection of multiple sets of nucleic-acids and transfer of molecules | Abandoned | 15-Dec-2014 | C12N15/1082 |
Fore (Drug Discovery) Executive Team (12)
Fore (Drug Discovery) Board Members (17)
| Name | Representing | Role | Since |
|---|---|---|---|
| Asaf Shinar | Pontifax Venture Capital | Board Member | 000 0000 |
| Chandra Leo MD | HBM Partners | Board Member | 000 0000 |
| Dieter Weinand | Self | Chairman | 000 0000 |
| Erez Chimovits | OrbiMed | Board Member | 000 0000 |
| Heiner Dreismann | Fore (Drug Discovery) | Board Member | 000 0000 |
Fore (Drug Discovery) Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Fore (Drug Discovery) Investors (15)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Cormorant Asset Management | Hedge Fund | Minority | 000 0000 | 000000 0 | |
| HBM Healthcare Investments | Venture Capital | Minority | 000 0000 | 000000 0 | |
| HBM Partners | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Novartis Venture Fund | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | |
| SR One | Venture Capital | Minority | 000 0000 | 000000 0 |